Format

Send to

Choose Destination
Endocr Connect. 2019 Jun 1. pii: EC-19-0206.R1. doi: 10.1530/EC-19-0206. [Epub ahead of print]

Molecular prognostic factors in small-intestinal neuro-endocrine tumours.

Author information

1
K Samsom, Pathology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands.
2
L van Veenendaal , Medical Oncology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands.
3
G Valk, Endocrinology, University Medical Center Utrecht, Utrecht, Netherlands.
4
M Vriens, Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
5
M Tesselaar, Medical Oncology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands.
6
J van den Berg, Pathology, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands.

Abstract

BACKGROUND:

Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogeneous group of rare tumours. In recent years, basic research in SI-NETs has attempted to unravel the molecular events underlying SI- NET tumorigenesis.

AIM:

We aim to provide an overview of the current literature regarding prognostic and predictive molecular factors in patients with SI-NETs.

METHOD:

A PubMed search was conducted on (epi)genetic prognostic factors in SI-NETs from 2000 until 2019.

RESULTS:

The search yielded 1522 articles of which 18 reviews and 35 original studies were selected for further evaluation. SI-NETs are mutationally quiet tumours with a different genetic make-up compared to pancreatic NETs. Loss of heterozygosity at chromosome 18 is the most frequent genomic aberration (44-100%) followed by mutations of CDKN1B in 8%. Prognostic analyses were performed in 16 studies, of which 8 found a significant (epi)genetic association for survival or progression. Loss of heterozygosity at chromosome 18, gains of chromosome 4,5, 7, 14 and 20p, copy gain of the SRC gene and low expression of RASSF1A and P16 were associated with poorer survival. In comparison with genetic mutations, epigenetic alterations are significantly more common in SI-NETs and may represent more promising targets in the treatment of SI-NETs.

CONCLUSION:

SI-NETs are mutationally silent tumours. No biomarkers have been identified yet that can easily be adopted into current clinical decision making. SI-NETs may represent a heterogeneous disease and larger international studies are warranted to translate molecular findings into precision oncology.

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center